Clinical efficacy of dienogest tablets in the treatment of pain associated with endometriosis or adenomyosis

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300068796

Enrollment

Unknown

Registered

2023-03-01

Start date

2023-03-01

Completion date

Unknown

Last updated

2023-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis

Interventions

dienogest treatment group:N/A

Eligibility

Sex/Gender

Female

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. Premenopausal women aged =18 years; 2. Endometriosis or adenomyosis diagnosed by B-ultrasound and clinical examination; 3. VAS score of pain associated with endometriosis or adenomyosis =3cm; 4. The subjects were informed and signed the informed consent form voluntarily.

Exclusion criteria

Exclusion criteria: 1. Pregnancy, lactation, and amenorrhea; 2. Recent fertility needs; 3. Unexplained vaginal bleeding; 4. Ovarian cyst diameter > 5cm; 5. Obvious uterine enlargement (uterine diameter > 10 cm or maximum myometrium thickness > 4 cm); 6. Severe menstrual bleeding to anemia (hemoglobin < 8g/dL); 7. Recent use of a hormonal agent (e.g., GnRH-a or another long-acting agent within 3 months, or short-acting within 1 month) Medicines such as oral contraceptives); 8. There are clear surgical indications for surgical treatment; 9. Any contraindications to study drugs; 10. Other investigators deem it inappropriate to participate.

Design outcomes

Primary

Measure	Time frame
pain;	—

Secondary

Measure	Time frame
Cyst size;Estrogen level;Other hormone levels;	—

Countries

China

Contacts

Public ContactHuaLi Wang

Dalian Women and Children's Medical Center (Group)

whl-dl@163.com13309856510

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026